Adeline Durand

Adeline Durand

Auto-generated profile, based on publicly available information

Adeline Durand

UMR3244, Translational Department, Institut Curie, PSL University, Paris, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KGKevin Grosselin
Kevin Grosselin
ADAdeline Durand
Adeline Durand
JMJustine Marsolier
Justine Marsolier
APAdeline Poitou
Adeline Poitou
EMElisabetta Marangoni
Elisabetta Marangoni
AGAnnabelle Gérard
Annabelle Gérard

11 April 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JMJustine Marsolier
Justine Marsolier
PPPacôme Prompsy
Pacôme Prompsy
ADAdeline Durand
Adeline Durand
ALAnne-Marie Lyne
Anne-Marie Lyne
CLCamille Landragin
Camille Landragin
CVCéline Vallot
Céline Vallot

12 August 2026 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
ASAnna Schwager
Anna Schwager
EMEve Moutaux
Eve Moutaux
ADAdeline Durand
Adeline Durand
AKAlexandra Van Keymeulen
Alexandra Van Keymeulen
AVAmélie Viaene
Amélie Viaene
CVCéline Vallot
Céline Vallot

19 October 2026 in Cancer Discovery
Verified
Journal Article
Closed access
YLYuna Landais
Yuna Landais
JBJuliette Bertorello
Juliette Bertorello
MPMarta Plasencia Puerto
Marta Plasencia Puerto
AKAgathe Kahn
Agathe Kahn
BSBaptiste Simon
Baptiste Simon
CVCéline Vallot
Céline Vallot
Non-genetic intratumor heterogeneity underlies therapeutic failure in cancer, yet how resistant tumor states are encoded in patients remains unclear. In this study, we show that chemoresistant evolution in high-grade serous ovarian cancer (HGSOC) is prefigured by epigenetically primed tumor cell states present before therapy. Using multimodal single-nucleus approaches, we profile transcriptional programs and histone modifications from longitudinal frozen biopsies of 16 patients with HGSOC. Tumors comprise a limited set of functional states that evolve reproducibly under chemotherapy: proliferative and IFN-responsive states are depleted, whereas TNFα-associated and epithelial-mesenchymal transition–associated programs persist or expand. Chromatin profiling reveals that these resistant programs are broadly enriched for histone H3 lysine 4 monomethylation (H3K4me1) prior to treatment, indicating that features of resistance are epigenomically primed. Baseline tumor composition is associated with survival, and fibroblast remodeling accompanies malignant adaptation. Together, these findings identify epigenomic priming as a feature of chemoresistant tumor cell states and provide a scalable framework for anticipating resistance from biopsies. Significance: Using a clinically compatible multimodal single-nucleus approach, the authors show that chemoresistant evolution in HGSOC is prefigured by epigenetically primed tumor cell states present before therapy.

11 November 2026 in Nature
Verified
Journal Article
Open access
NFNoa Furth
Noa Furth
CRChristina Riemenschneider
Christina Riemenschneider
YAYishai Arieli
Yishai Arieli
MAMatan Avni
Matan Avni
MPMichael-Yakov Povolotski
Michael-Yakov Povolotski
ESEfrat Shema
Efrat Shema
Breast cancer, the most diagnosed cancer among women, is stratified by gene expression patterns into luminal and basal-like subtypes, and the latter is associated with worse prognosis1-3. Recent advances in single-cell technologies have underscored the presence of intratumour heterogeneity, which poses substantial challenges in cancer treatment and achieving long-term disease-free survival4-7. Here we extensively profile epigenetic heterogeneity in a cohort of treatment-naive human luminal tumours, which were obtained directly after surgical resection. By applying a single-cell epigenetic approach based on cytometry by time-of-flight, we identify a recurrent subpopulation of basal-like cells in luminal tumours with a conserved epigenetic signature across patients. These basal-like cells, also identified by deconvolution of whole-genome DNA methylation patterns, are characterized by high expression of aggressive oncogenic traits and downregulation of hormone receptor signalling. Direct comparison of single-cell proteomic and genomic profiling of monomethylation and trimethylation of histone 3 on lysine 4 revealed that these marks are key features associated with loss of luminal identity. Finally, we highlight the potential of concomitant single-molecule profiling of histone modifications on cell-free nucleosomes in blood as an epigenetic liquid biopsy approach for early diagnosis of breast cancer. Moreover, the epigenetic basal signature measured in blood is linked to prognosis, which enables the identification of patients at increased risk for disease relapse.